FibroBiologics (FBLG) Competitors $0.58 +0.05 (+9.02%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.58 -0.01 (-1.10%) As of 08/8/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBLG vs. ZURA, SAVA, HLVX, COYA, CHRS, MGNX, CLYM, PLRX, ANIX, and ONCYShould you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Zura Bio (ZURA), Cassava Sciences (SAVA), HilleVax (HLVX), Coya Therapeutics (COYA), Coherus Oncology (CHRS), MacroGenics (MGNX), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. FibroBiologics vs. Its Competitors Zura Bio Cassava Sciences HilleVax Coya Therapeutics Coherus Oncology MacroGenics Climb Bio Pliant Therapeutics Anixa Biosciences Oncolytics Biotech FibroBiologics (NASDAQ:FBLG) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations. Which has higher earnings & valuation, FBLG or ZURA? Zura Bio is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroBiologicsN/AN/A-$11.16M-$0.36-1.62Zura BioN/AN/A-$45.39M-$0.70-2.03 Does the media refer more to FBLG or ZURA? In the previous week, FibroBiologics had 11 more articles in the media than Zura Bio. MarketBeat recorded 14 mentions for FibroBiologics and 3 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.78 beat FibroBiologics' score of 0.54 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is FBLG or ZURA more profitable? Zura Bio's return on equity of -42.84% beat FibroBiologics' return on equity.Company Net Margins Return on Equity Return on Assets FibroBiologicsN/A -710.25% -118.02% Zura Bio N/A -42.84%-35.22% Do institutionals and insiders believe in FBLG or ZURA? 61.1% of Zura Bio shares are owned by institutional investors. 20.8% of FibroBiologics shares are owned by company insiders. Comparatively, 22.1% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, FBLG or ZURA? FibroBiologics has a beta of -0.74, suggesting that its stock price is 174% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Do analysts prefer FBLG or ZURA? FibroBiologics presently has a consensus target price of $13.00, indicating a potential upside of 2,132.14%. Zura Bio has a consensus target price of $14.33, indicating a potential upside of 909.39%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities analysts plainly believe FibroBiologics is more favorable than Zura Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryZura Bio beats FibroBiologics on 7 of the 13 factors compared between the two stocks. Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBLG vs. The Competition Export to ExcelMetricFibroBiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.40M$2.99B$5.50B$9.72BDividend YieldN/A2.28%4.59%4.12%P/E Ratio-1.6217.1130.0524.70Price / SalesN/A330.47456.53100.55Price / CashN/A40.7324.8428.01Price / Book7.288.888.525.76Net Income-$11.16M-$54.75M$3.27B$267.05M7 Day Performance-10.21%0.01%6.13%5.08%1 Month Performance-10.26%0.64%0.07%0.61%1 Year Performance-70.44%8.71%36.43%22.83% FibroBiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBLGFibroBiologics3.4515 of 5 stars$0.58+9.0%$13.00+2,132.1%-70.4%$24.40MN/A-1.6210News CoverageAnalyst ForecastAnalyst RevisionZURAZura Bio3.8755 of 5 stars$1.46-2.7%$14.33+881.7%-58.1%$102.56MN/A-2.093Upcoming EarningsSAVACassava Sciences2.7004 of 5 stars$2.29+8.0%$54.50+2,279.9%-90.0%$102.41MN/A-1.5330News CoverageUpcoming EarningsHLVXHilleVax1.7287 of 5 stars$2.07+1.5%$2.00-3.4%+29.4%$102.29MN/A-0.9620News CoverageEarnings ReportUpcoming EarningsHigh Trading VolumeCOYACoya Therapeutics2.0795 of 5 stars$6.34+4.1%$16.50+160.3%+0.3%$101.86M$3.69M-5.936News CoverageUpcoming EarningsCHRSCoherus Oncology4.1557 of 5 stars$0.87-1.1%$4.68+439.6%-42.7%$101.77M$266.96M-0.77330News CoverageMGNXMacroGenics4.3356 of 5 stars$1.64+3.8%$5.33+225.2%-56.3%$99.68M$152.43M-1.84430Upcoming EarningsCLYMClimb Bio2.6817 of 5 stars$1.70+17.2%$9.00+429.4%N/A$97.99MN/A-0.719News CoverageUpcoming EarningsGap UpHigh Trading VolumePLRXPliant Therapeutics3.8457 of 5 stars$1.70+7.6%$13.31+683.1%-86.5%$96.99M$1.58M-0.4790News CoverageEarnings ReportAnalyst ForecastGap DownANIXAnixa Biosciences3.573 of 5 stars$3.26+8.3%$9.00+176.1%-5.1%$96.96M$210K-8.585Analyst ForecastONCYOncolytics Biotech2.294 of 5 stars$0.88-10.8%$4.33+390.7%-12.4%$96.43MN/A-3.0530News CoverageEarnings ReportGap Up Related Companies and Tools Related Companies ZURA Competitors SAVA Competitors HLVX Competitors COYA Competitors CHRS Competitors MGNX Competitors CLYM Competitors PLRX Competitors ANIX Competitors ONCY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBLG) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
